A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
Status:
Terminated
Trial end date:
2021-02-02
Target enrollment:
Participant gender:
Summary
This Phase 1b/2 study will examine the effects of the study drugs, avelumab, binimetinib and
talazoparib when given in a 2 (doublet) or 3 (triplet) drug combination, in patients with
locally advanced or metastatic RAS-mutant solid tumors. The Phase 1b part of the study will
assess if the different study drugs can be given together safely and which doses to use for
further research. Phase 2 will test if the study treatments have an effect on tumor size and
growth, and gather more information about potential side effects.